Teligent Inc (TLGT) Stock Price, Forecast & Analysis
USA - NASDAQ:TLGT -
TLGT Key Statistics, Chart & Performance
The current stock price of TLGT is 0.1735 null. In the past month the price decreased by -55.51%. In the past year, price decreased by -75.14%.
TLGT Latest News, Press Relases and Analysis
TLGT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.78 | 3.97B |
Related stock screener links
About TLGT
Company Profile
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. The company is headquartered in Buena, New Jersey and currently employs 142 full-time employees. The firm is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. The company also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States and Canada. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. In Canada, it markets approximately 24 generic injectable, one generic topical and three generic ophthalmic products.
Company Info
Teligent Inc
105 Lincoln Avenue
Buena NEW JERSEY 08310 US
CEO: Timothy B. Sawyer
Employees: 142
Phone: 18566971441.0
Teligent Inc / TLGT FAQ
What does TLGT do?
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. The company is headquartered in Buena, New Jersey and currently employs 142 full-time employees. The firm is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. The company also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States and Canada. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. In Canada, it markets approximately 24 generic injectable, one generic topical and three generic ophthalmic products.
What is the current price of TLGT stock?
The current stock price of TLGT is 0.1735 null. The price decreased by -13.85% in the last trading session.
What is the dividend status of Teligent Inc?
TLGT does not pay a dividend.
What is the ChartMill technical and fundamental rating of TLGT stock?
TLGT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of Teligent Inc (TLGT) based on its PE ratio?
Teligent Inc (TLGT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.24).
TLGT Technical Analysis
TLGT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TLGT. The financial health of TLGT is average, but there are quite some concerns on its profitability.
TLGT Financial Highlights
Over the last trailing twelve months TLGT reported a non-GAAP Earnings per Share(EPS) of -7.24. The EPS increased by 27.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -197.78% | ||
| ROA | -101.27% | ||
| ROE | N/A | ||
| Debt/Equity | -2.67 |
TLGT Forecast & Estimates
For the next year, analysts expect an EPS growth of 131.61% and a revenue growth -16.85% for TLGT